• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

活动性肢端肥大症中生长激素分泌过多程度的评估:不同采样模型的可靠性

Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: reliability of different sampling models.

作者信息

Bajuk Studen Katica, Barkan Ariel

机构信息

Division of Metabolism, Endocrinology and Diabetes, 3920 Taubman, SPC 5354, University of Michigan Medical Center, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109-5354, USA.

出版信息

J Clin Endocrinol Metab. 2008 Feb;93(2):491-6. doi: 10.1210/jc.2007-1451. Epub 2007 Nov 20.

DOI:10.1210/jc.2007-1451
PMID:18029464
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2243233/
Abstract

CONTEXT

The pulsatility of GH secretion in acromegaly poses difficulty in ascertaining true daily GH milieu in patients with this disease. Intensive GH sampling [every 10-20 (Q10-20) min for 24 h] is not practical in clinical practice.

OBJECTIVE

Our objective was to ascertain reliability of abbreviated sampling protocols to reflect true 24-h mean GH concentrations in patients with acromegaly.

DESIGN

An analysis of previously obtained plasma GH profiles was performed.

SETTING

The analysis was performed at the General Clinical Research Center at the University of Michigan.

PATIENTS

A total of 115 GH profiles obtained in 94 patients with active acromegaly were examined.

INTERVENTION

Frequent blood sampling, i.e. Q10-20 min for 24 h, was performed.

MAIN OUTCOME MEASURES

Concordance of 24-h mean GH concentrations derived from Q10- to 20-min samplings with abbreviated GH sampling schedules was performed. The study was planned after data collection.

RESULTS

All abbreviated schedules of GH sampling correlated well with the true 24-h plasma GH means (i.e. Q10- to 20-min sampling) (R = 0.93-0.98; P < 0.0001 for all). In the GH range more than 20 microg/liter, only 5 and 9-h means had R values more than 0.9. Single GH concentrations less than 1 microg/liter had a positive predictive value of only 0.29, and those with less than 2.5 microg/liter had a positive predictive value of 0.67 vs. their corresponding 24-h mean GH values of the same magnitude.

CONCLUSIONS

The intensity of GH sampling in patients with acromegaly may vary depending on the nature of the required information. Investigators and clinicians should be aware of the limitations of the abbreviated GH sampling protocols in acromegaly.

摘要

背景

肢端肥大症患者生长激素(GH)分泌的波动性使得确定该疾病患者的真实每日GH水平存在困难。在临床实践中,每10 - 20分钟(Q10 - 20)进行一次24小时的密集GH采样并不实际。

目的

我们的目的是确定简化采样方案反映肢端肥大症患者真实24小时平均GH浓度的可靠性。

设计

对先前获得的血浆GH谱进行分析。

地点

分析在密歇根大学综合临床研究中心进行。

患者

共检查了94例活动性肢端肥大症患者的115份GH谱。

干预

进行频繁采血,即每10 - 20分钟一次,共24小时。

主要观察指标

将每10 - 20分钟采样得到的24小时平均GH浓度与简化的GH采样方案进行一致性分析。该研究在数据收集后进行规划。

结果

所有简化的GH采样方案与真实的24小时血浆GH平均值(即每10 - 20分钟采样)相关性良好(R = 0.93 - 0.98;所有P < 0.0001)。在GH浓度超过20微克/升的范围内,只有5小时和9小时的平均值R值大于0.9。单次GH浓度低于1微克/升时,其阳性预测值仅为0.29,低于2.5微克/升时,与相应的相同量级的24小时平均GH值相比,阳性预测值为0.67。

结论

肢端肥大症患者GH采样的强度可能因所需信息的性质而异。研究者和临床医生应意识到肢端肥大症中简化GH采样方案的局限性。

相似文献

1
Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: reliability of different sampling models.活动性肢端肥大症中生长激素分泌过多程度的评估:不同采样模型的可靠性
J Clin Endocrinol Metab. 2008 Feb;93(2):491-6. doi: 10.1210/jc.2007-1451. Epub 2007 Nov 20.
2
Quantification of day-to-day variability in growth hormone levels in acromegaly.肢端肥大症患者生长激素水平的日常波动定量分析。
Pituitary. 2010 Dec;13(4):351-4. doi: 10.1007/s11102-010-0245-4.
3
Complex rhythmicity and age dependence of growth hormone secretion are preserved in patients with acromegaly: further evidence for a present hypothalamic control of pituitary somatotropinomas.肢端肥大症患者的生长激素分泌具有复杂的节律性和年龄依赖性:进一步证明下丘脑对垂体生长激素瘤具有控制作用。
J Clin Endocrinol Metab. 2013 Jul;98(7):2959-66. doi: 10.1210/jc.2013-1581. Epub 2013 May 2.
4
Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I.基础而非脉冲式的生长激素分泌决定了循环中胰岛素样生长因子-I 的环境水平。
J Clin Endocrinol Metab. 2010 May;95(5):2486-91. doi: 10.1210/jc.2009-2634. Epub 2010 Feb 26.
5
Optimizing Blood Sampling Protocols in Patients With Acromegaly for the Estimation of Growth Hormone Secretion.优化肢端肥大症患者的采血方案以估算生长激素分泌。
J Clin Endocrinol Metab. 2016 Jul;101(7):2675-82. doi: 10.1210/jc.2016-1142. Epub 2016 Mar 29.
6
Regulation of GH secretion in acromegaly: reproducibility of daily GH profiles and attenuated negative feedback by IGF-I.肢端肥大症中生长激素分泌的调节:每日生长激素谱的可重复性及胰岛素样生长因子-I负反馈减弱
J Clin Endocrinol Metab. 2001 Sep;86(9):4364-70. doi: 10.1210/jcem.86.9.7840.
7
Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?使用灵敏的生长激素检测法评估经治疗的肢端肥大症患者的疾病活动度:生化治愈是否应达到严格的正常生长激素水平?
J Clin Endocrinol Metab. 2002 Jul;87(7):3142-7. doi: 10.1210/jcem.87.7.8631.
8
Diminished and irregular thyrotropin secretion with preserved diurnal rhythm in patients with active acromegaly.活动期肢端肥大症患者促甲状腺激素分泌减少且不规则,但昼夜节律仍保留。
J Clin Endocrinol Metab. 2009 Jun;94(6):1945-50. doi: 10.1210/jc.2009-0174. Epub 2009 Mar 31.
9
Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.53例肢端肥大症术后患者的长期生化状态及疾病相关发病率
J Clin Endocrinol Metab. 2004 Feb;89(2):658-61. doi: 10.1210/jc.2003-030915.
10
Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.肢端肥大症手术治疗结果的预测因素及平均生长激素日曲线在评估术后疾病活动中的价值。
J Clin Endocrinol Metab. 2001 Apr;86(4):1645-52. doi: 10.1210/jcem.86.4.7398.

引用本文的文献

1
Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly.使用现代检测方法和参考范围解读生长激素和 IGF-1 结果,以监测肢端肥大症的治疗效果。
Front Endocrinol (Lausanne). 2023 Oct 25;14:1266339. doi: 10.3389/fendo.2023.1266339. eCollection 2023.
2
Mean GH profile is more accurate than single fasting GH in the evaluation of acromegaly disease control during somatostatin receptor ligands therapy.生长激素(GH)均值谱在评估生长抑素受体配体治疗期间肢端肥大症疾病控制方面比单次空腹 GH 更准确。
J Endocrinol Invest. 2022 Oct;45(10):1955-1965. doi: 10.1007/s40618-022-01830-6. Epub 2022 Jun 24.
3
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.3173 例来自列日肢端肥大症调查(LAS)数据库的患者的诊断时肢端肥大症。
Endocr Relat Cancer. 2017 Oct;24(10):505-518. doi: 10.1530/ERC-17-0253. Epub 2017 Jul 21.
4
"Micromegaly": an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era.“微小腺瘤型肢端肥大症”:现代时代伴看似正常 GH 分泌的肢端肥大症流行率的最新更新。
Pituitary. 2016 Dec;19(6):547-551. doi: 10.1007/s11102-016-0735-0.
5
Pharmacological treatment of acromegaly: its place in the overall therapeutic approach.肢端肥大症的药物治疗:其在整体治疗方法中的地位。
J Neurooncol. 2014 May;117(3):415-20. doi: 10.1007/s11060-013-1353-6. Epub 2014 Jan 18.
6
Tamoxifen as a therapeutic agent in acromegaly.他莫昔芬在肢端肥大症治疗中的应用。
Pituitary. 2014 Dec;17(6):500-4. doi: 10.1007/s11102-013-0534-9.
7
Optic neuropathy in McCune-Albright syndrome: effects of early diagnosis and treatment of growth hormone excess.McCune-Albright 综合征中的视神经病变:早期诊断和治疗生长激素过多的影响。
J Clin Endocrinol Metab. 2013 Jan;98(1):E126-34. doi: 10.1210/jc.2012-2111. Epub 2012 Oct 23.
8
The changing face of acromegaly--advances in diagnosis and treatment.肢端肥大症的变化面貌——诊断和治疗的进展。
Nat Rev Endocrinol. 2012 Oct;8(10):605-11. doi: 10.1038/nrendo.2012.101. Epub 2012 Jun 26.
9
Quantification of day-to-day variability in growth hormone levels in acromegaly.肢端肥大症患者生长激素水平的日常波动定量分析。
Pituitary. 2010 Dec;13(4):351-4. doi: 10.1007/s11102-010-0245-4.
10
Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?肢端肥大症的监测:当生长激素(GH)和胰岛素样生长因子-1(IGF-1)水平不一致时应进行哪些检查?
Clin Endocrinol (Oxf). 2009 Aug;71(2):166-70. doi: 10.1111/j.1365-2265.2009.03556.x. Epub 2009 Feb 18.

本文引用的文献

1
Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR.对于接受长效奥曲肽治疗的肢端肥大症患者的随访,两小时平均生长激素水平并不优于基础生长激素水平。
Growth Horm IGF Res. 2007 Feb;17(1):77-81. doi: 10.1016/j.ghir.2006.12.003. Epub 2007 Feb 20.
2
Medical progress: Acromegaly.医学进展:肢端肥大症。
N Engl J Med. 2006 Dec 14;355(24):2558-73. doi: 10.1056/NEJMra062453.
3
Clinical utility of measurements of insulin-like growth factor 1.胰岛素样生长因子1测量的临床效用。
Nat Clin Pract Endocrinol Metab. 2006 Aug;2(8):436-46. doi: 10.1038/ncpendmet0244.
4
GH and mortality in acromegaly.肢端肥大症中的生长激素与死亡率
J Endocrinol Invest. 2005;28(11 Suppl International):75-7.
5
Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study.奥曲肽长效注射剂治疗新诊断的伴有大腺瘤的肢端肥大症患者48周的疗效和安全性:一项开放标签、多中心、非对照研究。
J Endocrinol Invest. 2005 Dec;28(11):978-83. doi: 10.1007/BF03345335.
6
Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.奥曲肽长效注射剂对肢端肥大症的初始治疗:一项关于其控制疾病活动和肿瘤缩小疗效的长期(长达九年)前瞻性研究。
J Clin Endocrinol Metab. 2006 Apr;91(4):1397-403. doi: 10.1210/jc.2005-2347. Epub 2006 Jan 31.
7
A nationwide survey of mortality in acromegaly.一项关于肢端肥大症死亡率的全国性调查。
J Clin Endocrinol Metab. 2005 Jul;90(7):4081-6. doi: 10.1210/jc.2004-1381. Epub 2005 May 10.
8
Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements.单中心治疗的肢端肥大症患者生存的决定因素:胰岛素样生长因子I系列测量的预测价值
J Clin Endocrinol Metab. 2004 Jun;89(6):2789-96. doi: 10.1210/jc.2003-032041.
9
Factors influencing mortality in acromegaly.肢端肥大症患者死亡的影响因素。
J Clin Endocrinol Metab. 2004 Feb;89(2):667-74. doi: 10.1210/jc.2003-031199.
10
Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission.威尔士经蝶窦手术治疗肢端肥大症:基于严格缓解标准的结果
J Clin Endocrinol Metab. 2003 Aug;88(8):3567-72. doi: 10.1210/jc.2002-021822.